Condition 1: Migraine without aura. Condition 2: Migraine with aura. Migraine without aura [common migraine] Migraine:aura without headachebasilarequivalentsfamilial hemiplegicwith:acute-onset auraprolonged auratypical aura
Conditions
Interventions
Intervention 1: Intervention group: 44 migraine patient receive one tablet of 100 mg of coenzyme Q10 supplement and 1000 mg of omega 3(120 mg EPA and 180 mg DHA) daily for 8 weeks each. Intervention 2
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: All patients with episodic migraine whose condition has been confirmed by a specialist physician based on the ICHD_3 criteria They should have at least four attacks per month or one disabling attack per month They should receive treatment for headaches under the guidance of a specialist They should be between 18 and 50 years old They should have a body mass index (BMI) within the range of 18.5 to 29.9 Complete and sign informed consent
Exclusion criteria
Exclusion criteria: If they have other types of headaches, including tension headaches If they are menopausal If they have a history of heart attack, stroke, or other heart diseases If they have a serious issue with any organ, suffer from inflammatory or psychiatric diseases, or have a clotting disorder If they are pregnant or breastfeeding If, according to the treating doctor, they use acute migraine medications more frequently than usual If they have taken omega-3, coenzyme Q10, or other antioxidant supplements in the past month If they have untreated dental problems, based on their medical history if they have a history of brain surgery, based on their medical history if they have a history of high eye pressure, based on their medical history
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of headache characteristics (duration of migraine attacks, number of days with moderate to severe headaches, severity of associated symptoms, number of days without migraine symptoms and headaches, use of acute treatments and healthcare visits for headaches, headache intensity, and number of workdays missed due to migraines). Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Headache diary.;Total antioxidant capacity. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of total antioxidant capacity in the body.;Malondialdehyde. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Serum Malondialdehyde level.;Interleukin-6. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Serum Interleukin-6 level. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Migraine specific quality of life score.;Depression and anxiety. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Hospital Anxiety and Depression scale score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Reza Vafa
Iran University of Medical Sciences
Outcome results
None listed